Rapid cancer diagnostic technologies are assay formats and instruments designed to measure a cancer-associated biomarker near the point of sampling, without sending the specimen to a central laboratory. The main…
Fluorescent and gold nanoparticle lateral flow assays share the same strip and the same antibody chemistry; they differ in the label attached to the detection antibody and in how the…
Our primary corporate website is now OncoFirm.com.
Visit our main website for the latest information about our cancer diagnostic technologies, research programs, intellectual property, corporate developments, partnerships and investor opportunities.
Continue to OncoFirm.com